预约演示
更新于：2025-05-16
Epinastine Hydrochloride
盐酸依匹斯汀
更新于：2025-05-16
概要
基本信息
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C16H16ClN3 |
InChIKeyVKXSGUIOOQPGAF-UHFFFAOYSA-N |
CAS号108929-04-0 |
关联
51
项与 盐酸依匹斯汀 相关的临床试验CTR20243732
盐酸依匹斯汀片在健康受试者中的单中心、随机、开放、单次给药、两制剂、两序列、两周期、双交叉、空腹及餐后状态下的生物等效性研究
CTR20234212
0.1%STN1011403滴眼液治疗过敏性结膜炎的多中心随机评价者盲态阳性对照试验
CTR20231572
0.05%盐酸依匹斯汀滴眼液治疗中国过敏性结膜炎患者的有效性和安全性的随机、双盲、阳性药平行对照、多中心临床研究
100 项与 盐酸依匹斯汀 相关的临床结果
登录后查看更多信息
100 项与 盐酸依匹斯汀 相关的转化医学
登录后查看更多信息
100 项与 盐酸依匹斯汀 相关的专利（医药）
登录后查看更多信息
310
项与 盐酸依匹斯汀 相关的文献（医药）2025-04-01CHEMOSPHERE
Abating a micropollutant epinastine by UV-based advanced oxidation processes: Comparison for UV/hydrogen peroxide, UV/persulfate, and UV/chlorine, impacts of bromide contents, and formation of DBPs during post-chlorination
Article
作者: Murata, Yuichiro ; Sakai, Hiroshi
Anthropogenic organic compounds, such as pharmaceuticals and personal care products, contaminate water, posing toxicological risks caused by either their parent compounds or transformation products. This study compares ultraviolet (UV)-based advanced oxidation processes (UV/hydrogen peroxide, UV/persulfate, and UV/chlorine) for the abatement of an antihistamine drug epinastine. UV light at 254 nm was irradiated upon solutions containing 10 μM epinastine and 100 μM oxidant. UV/chlorine degraded epinastine most effectively at pH 6.0-8.0; considerable contributions by reactive chlorine species and hydroxyl radicals were quantified using probe compounds. Furthermore, the degradation efficiency of the UV/chlorine treatment persisted with a halved chlorine dosage. Additionally, the types and concentrations of disinfection byproducts (DBPs) produced during UV/chlorine treatment with or without post-chlorination varied depending on the concentrations of chlorine or bromide. By comparing estimated DBP formations at a constant degradation rate of epinastine, UV/chlorine formed smaller concentrations of DBPs. Consequently, this study experimentally revealed that UV/chlorine is superior to UV/hydrogen peroxide and UV/persulfate for degrading epinastine at the possible pH and bromide content in the environment and controlling toxicological risks caused by disinfection DBPs formation by optimising chlorine dosage and UV fluence.
2025-03-31PHARMAZIE
Direct comparison of the effects of first- and second-generation H1 -receptor blockers on motor functions in mice.
Article
作者: Hori, S ; Tenjin, K ; Shimada, A ; Kizu, J ; Sakamoto, Y ; Iketani, O ; Hara, R ; Matsumoto, K ; Enoki, Y ; Taguchi, K ; Okamoto, Y
Histamine H1 receptor (H1R) antagonists are widely used to treat allergic reactions; however, their effects on the central nervous system can impair motor functions. This study investigated the impact of first-generation (diphenhydramine and d -chlorpheniramine) and second-generation (epinastine, ketotifen, bepotastine, and levocetirizine) H1R antagonists on motor functions in mice using activity wheel, balance beam, inclined screen, and rotarod tests. First-generation H1R antagonists significantly impaired motor functions, with diphenhydramine exerting stronger effects than those of d -chlorpheniramine. Among the second-generation agents, bepotastine and levocetirizine had minimal effects on all motor functions, whereas epinastine and ketotifen suppressed spontaneous movement, similar to first-generation H1R antagonists but had little effects on balance, postural stability, and coordinated movement. These findings provide valuable insights into the differential effects of first- and second-generation H1R antagonists on motor functions. These results highlight the importance of understanding individual profiles of H1R antagonists to minimize adverse effects, ensure patient safety, and improve quality of life.
2025-02-28Cureus Journal of Medical Science
Successful Transition From Topical Ophthalmic Drops to Cream Formulation in the Management of Mild Allergic Conjunctivitis: A Case Report
Article
作者: Nishio, Mai ; Fujishima, Hiroshi ; Shimizu, Eisuke ; Fukagawa, Kazumi ; Asai, Kazuki
This case report highlights the successful transition from epinastine eye drops to a novel epinastine eyelid cream in managing mild allergic conjunctivitis. A 33-year-old Japanese female with mild allergic conjunctivitis, previously managed with 0.1% epinastine hydrochloride eye drops, requested an alternative formulation due to daily contact lens wear. Treatment was changed to a once-daily application of 0.5% epinastine hydrochloride eyelid cream. Clinical assessment and symptom evaluation were performed at baseline and after 28 days using slit-lamp examination and the Japanese Allergic Conjunctival Disease Quality of Life Questionnaire. Following the transition, the patient's clinical signs (mild conjunctival hyperemia and moderate papillae) and subjective symptoms (itching and mild discomfort) remained stable. Slit-lamp examination showed no corneal or limbal pathology, and tear fluid immunoglobulin E (IgE) testing remained positive, consistent with mild allergic conjunctivitis. No adverse effects or cutaneous reactions were observed. This case suggests that epinastine eyelid cream may serve as an effective once-daily alternative to conventional eye drops in mild allergic conjunctivitis. While this represents the first documented successful transition between delivery methods, larger clinical trials are warranted to confirm these findings and explore applications across various presentations and severities of allergic ocular disease.
100 项与 盐酸依匹斯汀 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 变应性结膜炎 | 日本 | 2013-09-20 | |
| 季节性过敏性结膜炎 | 奥地利 | 2003-03-04 | |
| 季节性过敏性结膜炎 | 比利时 | 2003-03-04 | |
| 季节性过敏性结膜炎 | 捷克 | 2003-03-04 | |
| 季节性过敏性结膜炎 | 丹麦 | 2003-03-04 | |
| 季节性过敏性结膜炎 | 法国 | 2003-03-04 | |
| 季节性过敏性结膜炎 | 德国 | 2003-03-04 | |
| 季节性过敏性结膜炎 | 希腊 | 2003-03-04 | |
| 季节性过敏性结膜炎 | 匈牙利 | 2003-03-04 | |
| 季节性过敏性结膜炎 | 爱尔兰 | 2003-03-04 | |
| 季节性过敏性结膜炎 | 意大利 | 2003-03-04 | |
| 季节性过敏性结膜炎 | 卢森堡 | 2003-03-04 | |
| 季节性过敏性结膜炎 | 荷兰 | 2003-03-04 | |
| 季节性过敏性结膜炎 | 波兰 | 2003-03-04 | |
| 季节性过敏性结膜炎 | 葡萄牙 | 2003-03-04 | |
| 季节性过敏性结膜炎 | 斯洛伐克 | 2003-03-04 | |
| 季节性过敏性结膜炎 | 西班牙 | 2003-03-04 | |
| 季节性过敏性结膜炎 | 瑞典 | 2003-03-04 | |
| 季节性过敏性结膜炎 | 英国 | 2003-03-04 | |
| 银屑病 | 中国 | 2000-06-16 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 季节性过敏性鼻炎 | 临床3期 | - | 2007-12-18 | |
| 特应性皮炎 | 临床3期 | - | 2001-06-01 | |
| 常年性变应性鼻炎 | 临床3期 | - | 2000-05-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床3期 | 87 | (Epinastine (DE-114) Ophthalmic Solution) | 製選廠積網鑰醖醖遞蓋(鑰夢醖鏇簾鬱製選鹹窪) = 壓鹽廠遞餘築夢醖壓餘 壓鏇餘願淵遞艱簾壓築 (膚觸艱壓餘糧夢範衊憲, 0.1) 更多 | - | 2014-11-05 | ||
Placebo (Placebo Ophthalmic Solution) | 製選廠積網鑰醖醖遞蓋(鑰夢醖鏇簾鬱製選鹹窪) = 鏇觸蓋築壓蓋顧觸製鏇 壓鏇餘願淵遞艱簾壓築 (膚觸艱壓餘糧夢範衊憲, 0.1) 更多 | ||||||
临床3期 | 130 | 繭鹽齋窪獵選衊蓋廠艱(艱鬱範衊夢鑰積夢廠選) = 遞廠壓範壓襯構糧獵襯 衊網築襯獵齋獵齋範簾 (鹽製鬱醖鏇繭構遞構淵, 0.1) 更多 | - | 2014-09-23 | |||
临床4期 | 79 | (Elestat) | 餘獵鑰艱壓淵淵廠製廠(簾築網齋獵遞廠繭鹹選) = 選糧壓範選憲簾製廠憲 築願獵壓構壓廠襯鑰膚 (蓋鑰遞繭窪鑰構憲鑰壓, 1.36) 更多 | - | 2009-05-27 | ||
(Pataday) | 餘獵鑰艱壓淵淵廠製廠(簾築網齋獵遞廠繭鹹選) = 襯網窪窪糧醖淵顧夢築 築願獵壓構壓廠襯鑰膚 (蓋鑰遞繭窪鑰構憲鑰壓, 1.07) 更多 | ||||||
N/A | 99 | Epinastine HCl 0.05% | 簾齋廠鏇選壓衊壓簾簾(壓糧築積簾膚齋窪鑰蓋) = Three (5.9%) epinastine patients and 7 (14.6%) ketotifen patients experienced adverse events. Treatment-related sleep disorder was reported for 2 ketotifen-treated patients, but was not found in epinastine-treated patients. 廠製構獵選蓋範簾觸網 (繭窪鏇鑰遞築積顧夢淵 ) | - | 2004-05-01 | ||
N/A | - | Epinastine HCl 0.05% | 顧獵網蓋艱餘顧鏇衊蓋(鑰觸網築網製鬱築淵鏇) = 範糧築壓襯蓋夢蓋蓋觸 餘鏇壓鹹餘憲鹹淵觸範 (壓憲顧窪糧積糧夢簾繭 ) | 积极 | 2003-05-01 | ||
顧獵網蓋艱餘顧鏇衊蓋(鑰觸網築網製鬱築淵鏇) = 夢製醖襯膚餘憲簾鹽網 餘鏇壓鹹餘憲鹹淵觸範 (壓憲顧窪糧積糧夢簾繭 ) | |||||||
N/A | 14 | 遞簾遞醖願艱構繭廠觸(鹹繭遞範艱獵憲選繭齋) = No adverse events nor any clinically relevant changes in visual acuity, biomicroscopy, ophthalmoscopy, vital signs, physical examination, or laboratory parameters were observed during the study 餘鏇遞憲鹹觸顧築齋壓 (範憲網積糧襯願積窪繭 ) | 积极 | 2003-05-01 | |||
N/A | - | - | Epinastine HCl 0.05% | 夢餘築簾襯齋齋網鏇選(醖齋憲簾網網鑰醖網壓) = primarily colds/URI, was the most frequent AE reported in 5.0% of epinastine subjects and 8.3% of vehicle subjects 網艱獵遞願糧積觸艱餘 (築膚遞鬱蓋衊獵醖淵網 ) | 积极 | 2003-05-01 | |
Vehicle |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用